Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

URGN – UroGen Pharma Ltd.

UroGen Pharma Ltd.
URGN
$19.40
Name : UroGen Pharma Ltd.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $896,305,216.00
EPSttm : -3.01
finviz dynamic chart for URGN
UroGen Pharma Ltd.
$19.40
1.78%
$0.34

Float Short %

18.37

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

0.29

EPS Last/This Y

0.08

EPS This/Next Y

1.84

Price

19.4

Target Price

34.38

Analyst Recom

1.25

Performance Q

70.03

Relative Volume

0.33

Beta

1.13

Ticker: URGN




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04URGN13.580.280.3057918
2025-07-07URGN13.460.280.1058011
2025-07-08URGN13.710.280.0558168
2025-07-09URGN13.830.281.5258537
2025-07-10URGN14.640.280.1359034
2025-07-11URGN14.210.280.1059567
2025-07-14URGN14.470.280.6959569
2025-07-15URGN14.040.280.4159685
2025-07-16URGN14.30.280.1359570
2025-07-17URGN15.40.280.2059453
2025-07-18URGN15.290.280.0460657
2025-07-21URGN15.380.270.0929892
2025-07-22URGN16.940.260.1031244
2025-07-23URGN18.660.250.4832965
2025-07-24URGN17.970.270.6435040
2025-07-25URGN18.980.290.2335585
2025-07-28URGN18.880.290.7736036
2025-07-29URGN18.910.291.1036110
2025-07-30URGN19.210.300.0336781
2025-07-31URGN19.060.300.0836807
2025-08-01URGN19.40.300.1036844
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04URGN13.589.0- -2.88
2025-07-07URGN13.489.0- -2.88
2025-07-08URGN13.719.0- -2.88
2025-07-09URGN13.819.0- -2.88
2025-07-10URGN14.649.0- -2.88
2025-07-11URGN14.249.0- -2.88
2025-07-14URGN14.499.0- -2.88
2025-07-15URGN14.049.0- -2.88
2025-07-16URGN14.329.0- -2.88
2025-07-17URGN15.419.0- -2.88
2025-07-18URGN15.289.0- -2.88
2025-07-21URGN15.479.0- -2.88
2025-07-22URGN16.949.0- -2.88
2025-07-23URGN18.669.0- -2.88
2025-07-24URGN18.009.0- -2.88
2025-07-25URGN18.959.0- -2.88
2025-07-28URGN18.819.0- -2.88
2025-07-29URGN18.909.0- -2.88
2025-07-30URGN19.229.0- -2.88
2025-07-31URGN19.069.0- -2.88
2025-08-01URGN19.409.0- -2.88
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04URGN-0.2628.6215.46
2025-07-07URGN-0.2628.6715.46
2025-07-08URGN-0.2628.6715.46
2025-07-09URGN-0.2628.6715.46
2025-07-10URGN-0.2628.6715.46
2025-07-11URGN-0.2628.6713.76
2025-07-14URGN-0.2628.5113.76
2025-07-15URGN-0.2628.5113.76
2025-07-16URGN-0.2628.5113.76
2025-07-17URGN-0.2628.5113.76
2025-07-18URGN-0.2628.5113.76
2025-07-21URGN-0.2628.5313.73
2025-07-22URGN-0.2628.5313.73
2025-07-23URGN-0.2628.5313.73
2025-07-24URGN-0.2628.5313.73
2025-07-25URGN-0.2628.5318.37
2025-07-28URGN-0.2629.3218.37
2025-07-29URGN-0.2629.3218.37
2025-07-30URGN-0.4629.3218.37
2025-07-31URGN-0.4629.3218.37
2025-08-01URGN-0.4629.3218.37
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

-0.92

Avg. EPS Est. Current Quarter

-0.83

Avg. EPS Est. Next Quarter

-0.63

Insider Transactions

-0.46

Institutional Transactions

29.32

Beta

1.13

Average Sales Estimate Current Quarter

23

Average Sales Estimate Next Quarter

33

Fair Value

Quality Score

24

Growth Score

50

Sentiment Score

88

Actual DrawDown %

31.2

Max Drawdown 5-Year %

-85.4

Target Price

34.38

P/E

Forward P/E

PEG

P/S

9.76

P/B

P/Free Cash Flow

EPS

-3.18

Average EPS Est. Cur. Y​

-2.88

EPS Next Y. (Est.)

-1.04

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-150.68

Relative Volume

0.33

Return on Equity vs Sector %

274.2

Return on Equity vs Industry %

292.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

UroGen Pharma Ltd.
Sector: Healthcare
Industry: Biotechnology
Employees: 234
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today
news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025
marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance
stock history URGN – UroGen Pharma Ltd. invest stock market
stock prices URGN premarket after hours
ticker URGN fair value insiders trading